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Abstract Placebo-controlled trials of pre-exposure pro-
phylaxis (PrEP) have reported challenges with study-pro-
duct uptake and use, with the greatest challenges reported
in studies with young women in sub-Saharan Africa. We
conducted a qualitative sub-study to explore experiences
with open-label PrEP among young women in Cape Town,
South Africa participating in HTPN 067/Alternative Dos-
ing to Augment Pre-Exposure Prophylaxis Pill Taking
(ADAPT). HPTN 067/ADAPT provided open label oral
FTC/TDF PrEP to young women in Cape Town, South
Africa who were randomized to daily and non-daily PrEP
regimens. Following completion of study participation,
women were invited into a qualitative sub-study including
focus groups and in-depth interviews. Interviews and
groups followed a semi-structured guide, were recorded,
transcribed, and translated to English from isiXhosa, and
coded using framework analysis. Sixty of the 179 women
enrolled in HPTN 067/ADAPT participated in either a
focus group (six groups for a total of 42 participants) or an
in-depth interview (n = 18). This sample of mostly young,
unmarried women identified facilitators of and barriers to
PrEP use, as well as factors influencing study participation.
Cross-cutting themes characterizing discourse suggested
that women placed high value on contributing to the well-
being of one’s community (Ubuntu), experienced a degree
of skepticism towards PrEP and the study more generally,
and reported a wide range of approaches towards PrEP
(ranging from active avoidance to high levels of persis-
tence and adherence). A Mutuality Framework is proposed
that identifies four dynamics (distrust, uncertainty, align-
ment, and mutuality) that represent distinct interactions
between self, community and study and serve to contex-
tualize women’s experiences. Implications for better
understanding PrEP use, and non-use, and intervention
opportunities are discussed. In this sample of women, PrEP
use in the context of an open-label research trial was
heavily influenced by underlying beliefs about safety,
reciprocity of contributions to community, and trust in
transparency and integrity of the research. Greater attention
to factors positioning women in the different dynamics of
the proposed Mutuality Framework could direct interven-
tion approaches in clinical trials, as well as open-label
PrEP scale-up.
Keywords PrEP  Open-label  Women  Adherence 
Mutuality framework  Barriers  South Africa
Introduction
HIV prevention science has produced considerable
advances in recent years, with clinical trials demonstrating
effectiveness of oral pre-exposure prophylaxis (PrEP) for
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prevention of HIV transmission [1–4]. Results from the
iPrEx randomized controlled trial (RCT) [3], Partners PrEP
study [1], and CDC’s TDF2 study [4] led to US Food and
Drug Administration approval of an indication for the first
publically available medication to prevent HIV [5]. Recent
findings from IPERGAY [6] and PROUD [7], both
involving PrEP in cohorts of men who have sex with men
(MSM) in France and Canada and the UK, respectively,
provide additional support for the effectiveness of PrEP. In
contrast, results from the FEM-PrEP study [8] and VOICE
[9], both involving women in sub-Saharan Africa, did not
demonstrate effectiveness of oral PrEP in the setting of
very low rates of PrEP use (cf., [10]). Varying rates of
adherence to study product has become a well-recognized
threat in PrEP trials and projects [11].
In the wake of the low study-product use observed in
studies with sub-Saharan African women, concerns have
been raised about the overall acceptability and feasibility of
oral PrEP regimens in this population. However, recent
qualitative explorations of factors that may have influenced
product use in these trials [12–15] suggest that aspects of
being in a trial testing an investigational biomedical agent
may have heavily influenced product non-use. Feelings
towards the research, such as overall support for the pro-
ject’s goals [12] or alternatively ambivalence towards it
[15] influenced use and non-use. It is possible that issues
inherent in clinical trials with investigational drugs may not
generalize to acceptability or feasibility of open-label
PrEP. To date, however, experiences among women in sub-
Saharan African women with open-label PrEP, specifically,
have not been characterized.
The HPTN 067/ADAPT trial was one of the first open
label PrEP studies to be conducted with women in sub-
Saharan Africa [16]. This Phase II, randomized, open-label
clinical trial of oral emtricitabine/tenofovir disoproxil
fumarate (FTC/TDF) PrEP investigated whether non-daily
versus daily regimens resulted in equivalent prophylactic
pre- and post-sex coverage. After 6 weeks of once a week
directly observed dosing, participants were randomly
assigned to one of three unblinded PrEP dosing regimens
for 24 weeks of self-administration: daily, twice weekly
with a post-sex dose, or event-driven with before and after
sex dosing. Only the daily regimen was known to be
effective while the study was conducted, and the other two
non-daily regimens were presented to participants as
investigational.
The aim of HPTN 067/ADAPT was presented to par-
ticipants as focused on participants’ real-world experiences
with trying to follow their assigned regimen. Non-adher-
ence was framed as an important and understandable
experience and participants were supported with education
around their assigned regimen, skills building for dosing-
schedules and forecasting of sexual events, and
motivational support through Next Step Counseling [17] at
each study visit. Pills were dispensed from a WisepillTM
device that recorded each opening and weekly interviews
with interviewers tasked solely with collecting pill-taking
and sex event data without feedback to study counsellors or
clinicians were conducted.
Three sites took part in HPTN 067/ADAPT, including a
site in Cape Town, South Africa enrolling heterosexual
women, and sites in Bangkok, Thailand and New York
City, USA, enrolling men who have sex with men and
transgender women. To explore South African women’s
experiences with open-label PrEP provided within the
context of a research study, we conducted a qualitative sub-
study with women participating in HPTN 067/ADAPT at
the Cape Town site. The aim of the qualitative sub study
was to provide a nuanced understanding of PrEP use in the
context of individual, community, study, and product
dynamics. Specifically, we sought to identify global and
regimen specific facilitators and barriers to study-provided
PrEP use and participation in the open-label PrEP study,
and the overarching cross-cutting themes in the narratives
that contextualized women’s experiences. Similar to pre-
vious work in this area [14], we approached the data with
the assumption that the levels identified in the socioeco-
logical model would generally organize emerging themes.
We sought to extend our understanding of these factors by
proposing how these levels interact to explain various
approaches participants had towards study-provided PrEP
across the full range of use and non-use, which reflected
initiation or uptake (or avoidance of it), persistence
(essentially, adoption of the regimen as something the
participant is trying to do), and adherence execution (extent
to which the participant is following the dose requirements
of the regimen). These approaches to PrEP use emanated
from discourse in the current study, but is generally com-
parable to a recently proposed typology generated from
qualitative work in the VOICE study, where patterns of
study-product use included non-initiation, discontinuation,
mis-implementation, and adherence [18].
In addition to presenting participant reported facilitators
and barriers, we identify overarching cross-cutting themes
that appeared to characterize aspects of participation and
PrEP use that were particularly influential to participant
experiences. Drawing from these results, related literature
[13–15, 19], and well-vetted social behavioral (socio-eco-
logical [20] and attitude formation [21]) and community
(community based participatory research [22]) models, we
propose an organizing framework (a Mutuality Frame-
work) to explain different participant approaches to study-
provided PrEP. We propose that a participant’s approach to
study-provided PrEP is the direct result of a specific,
definable interplay between participant, study, and com-
munity factors, which depend heavily on one’s sense of
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trust in PrEP. The framework encompasses four dynamics
labeled by the dominating type of relationship women in
that dynamic are anticipated to have with PrEP and the
institutions providing it (in the current case, the study): (1)
distrust, (2) uncertainty, (3) alignment and (4) mutuality.
Intervention strategies targeting enhancing alignment (i.e.,
positive beliefs in PrEP and goals of the research project)
and mutuality (i.e., sense of ownership over and advocacy
towards PrEP and goals of the research project) are
suggested.
Methods
From the 179 women randomised to one of the three reg-
imens in the parent study, we planned to recruit a total of
60 participants (34 % of total sample) for participation in
either focus group (FG) discussions or in-depth interviews
(IDIs), with a similar interview-guide used for FG and
IDIs. Per arm, two FGs and six IDIs were planned (for a
total of six FGs and 18 IDIs). Sample size was advised by
‘information power’ [23], where our targeted recruitment
reflected the discrete aims of the study and the specificity in
inquiry (e.g., use of the same basic semi-structured guide in
all FGs and IDIs) and participant groups (e.g., all attended
the same clinic, interacted with product, and resided in the
same general community). Inclusion criteria for the quali-
tative sub-study was having finished the on-drug portion of
the study (study week 34), while exclusion was having
finished over 3-months ago. Convenience sampling was
used to identify FG participants, where eligible women
were informed of open spots in planned FGs and referred to
a coordinator if interested. IDI participants were identified
with a combination of convenience and targeted sampling,
where attempts were made to include at least two partici-
pants from each arm who may have had low adherence
based on staff impressions (not WisepillTM or drug level
testing as that data was not yet available at time of
recruitment). Similar to FG recruitment, women were
informed of open spots for interviews and scheduled if
interested.
FGs and IDIs were conducted in participant preferred
language (isiXhosa or English) by an independent experi-
enced interviewer who was not part of the clinical study
team and had several years of experience in conducting
qualitative interviews with women in the communities
surrounding the research site. The development of the
interview guide and the approach to analysis of data was
situated within a socio-ecological framework [20] and
aspects of the information, motivation and behavioral skills
model [24] adapted to the current context. The main areas
of inquiry from the interview-guide are presented in
Table 1.
Data was transcribed and translated into English and
analysed using a thematic framework analysis approach
[25–27]. Two trained coders sorted transcribed discourse
into ‘‘frames’’ determined by interviewer inquiry (which
was based on the semi-structured guide). Each frame was
then iteratively reviewed for main themes in participant
responses to interviewer inquiries. The coding team met
throughout this process to review and refine themes, with
any disagreements resolved through discussion. Methods
were less to ensure interrater reliability [28] than to pro-
mote adaptions in the code book that leverage unique
insights of coders to create a common, nuanced under-
standing of frames and themes, which has been evaluated
as an approach that produces high level of agreement [29].
Final codes and themes had consensus between coders.
Themes in each frame and example quotes supporting the
themes were identified, followed by a review and synthesis
of all framed content spanning across multiple areas to
identify individual, local, cultural or group beliefs and
experiences that contextualized women’s experiences in
the study. Important observations from the qualitative data
that were not well captured in the thematic coding from the
framework analyses were also evaluated for potential
inclusion in cross-cutting themes. These cross-cutting
themes advised our formation of a Mutuality Framework
Table 1 Interview guide areas of inquiry for focus groups (FGs) and in-depth-interviews (IDIs)
Domain Inquiries/prompts
Feasibility/acceptability Perceptions of feasibility, acceptability and ease of uptake for their assigned regimen
Alteration of regimen Altering the regimen to better ‘fit’ their daily life or risk behavior
Preference for other regimens Whether participant(s) would switch to a different regimen if available; what the ideal regimen
would be
Facilitators and barriers to adherence Common facilitators and barriers to following assigned regimen
Disclosure of participation Sense of importance that others knew the participant was enrolled in the study
Experiences with participation and study
team
Feelings towards participation, the project, project-staff, and how pill-taking and condom use was
supported
Recommendations Recommendations for change in study support or adherence support approach
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that sought to explain women’s different approaches to
study-provided PrEP on the basis of interactions between
the participant, the study and study-provided PrEP, and the
community. Model development was led by the lead author
with iterative vetting with the coding team and the site’s
community liaisons.
Results
Participants
As planned, 60 women participated in the sub-study (42 in
focus groups and 18 in interviews). Women were
18–44 years of age (average 26, SD 7), with the majority
under the age of 25. The vast majority (90 %) were not
married. Both younger age and being unmarried distin-
guished the sub-study participants from the study cohort,
however the groups were comparable on other demo-
graphic or sexual behaviour data.
Themes
Facilitators of and Barriers to Study-Provided PrEP Use
As detailed in Table 2, several themes emerged in discourse
surrounding facilitators of adherence to the study-provided
PrEP pills. This content was organized into the following
themes: (1) Efficacy beliefs in PrEP providing effective
protection against HIV, (2) perceived HIV-prevention
needs/risks highlighted in discourse around enhanced sense
of vulnerability to HIV and identifying PrEP use as a source
of protection in the event of rape or forced sex, (3) use of
concrete adherence strategies such as reminders or pocket
dosing, and (4) social support from important significant
others that provided concrete help with dose-taking and also
removed study-participation disclosure-related barriers.
Barriers to adherence, presented in Table 2, included; (1)
Attributes of the PrEP pills (e.g., taste and smell) that made
dosing unpleasant, (2) perceived side-effects reported lar-
gely as nausea and headaches either experienced directly or
indirectly through reports of other participants, (3) ARV-
related stigma associated with others assuming the partici-
pant is/was HIV-positive because of being seen taking
‘‘HIV-medications’’, and (4) needs for privacy or non-dis-
closure to important others making dosing more difficult or
not possible without risk of undesired disclosure of being
part of the study. Specific to non-daily arms, discussion on
sex-dependent dosing revealed challenges in predicting sex
for pre-sex dosing, but largely centred on difficulty with
post-sex dosing because of a perceived mis-match between
relaxation or rest following sex and the action-oriented steps
needed to take a post-sex dose. Themes and example quotes
in Table 2 highlight experiences intentionally limited to
facilitators and challenges discussed in relation to dose tak-
ing (i.e., regimen execution); other factors that influenced
multiple aspects of participation in the study are presented
separately below in themes for study participation and
engagement more generally. Of note, several of the factors
eroding participation in the study noted below have clear
implications for also creating challenges to adherence.
Facilitators of and Challenges to Study Participation
Discourse reflecting reasons for participation, positive or
negative consequences of participation, and level of com-
mitment towards and belief in the value of the study and
outcomes were reviewed for main themes reflecting facil-
itators of participation and, conversely, factors challenging
participation (Table 3). Participant reflections on facilita-
tors to study engagement were organized into five general
themes; (1) Personal experiences with HIV enhancing
commitment towards the goals of the study, (2) valuing the
package of care received as a participant as unique and
beneficial, (3) financial/economic compensation offsetting
burden of participation, (4) positive feelings towards the
research team, and (5) commitment to HIV prevention
research as a benefit to one’s community. Discourse
highlighting potential factors negatively impacting full
participation or engagement in the study included; (1)
Concerns about safety of PrEP and confluence of directly
or indirectly experienced side-effects exacerbating these
concerns, (2) community distrust of study and/or PrEP and
women’s participation in the study expressed as beliefs
women were getting treatment for HIV, the clinic was
selling blood collected from participants, and devaluation
of participants as only interested in money, not community
prevention, and (3) negative clinic experiences largely
involving discomfort with sexual behaviour questions and a
lack of transparency in what was being done with that
information, as well as feeling wrongly accused of non-
adherence. As indicated in the sample quotes in Table 3,
women discussed both sources of pride in being an active
participant as well as considerable ‘‘cost’’ in terms of
negative pressure from community members and important
others. This tension was evidenced across discourse,
leading to the further identification of overarching cross-
cutting themes that better captured potential drivers,
responses and management of these tensions.
Cross-Cutting Themes/Narratives Contextualizing
Approach to Study-Provided PrEP
Several underlying ‘‘cross-cutting’’ themes were identified.
Two reflected cultural contextual factors that likely influ-
enced women’s overall experiences in the study and with
1364 AIDS Behav (2017) 21:1361–1375
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Table 2 Facilitators of and barriers to study-provided PrEP use
Theme Defined as discourse on… Example quotes
Facilitators of PrEP use
Efficacy beliefs Beliefs that PrEP works to prevent HIV ‘What motivated me is the fact that they protect me from
getting HIV, because sometimes I forget to use a condom
with my boyfriend that is why I continued using the pills. I
had that hope that the pills will protect me…’’ D IDI
‘‘The treatment made me safe so I continued taking the pills.’’
E IDI
‘‘I heard here at the site that these pills work and that they were
being tested overseas too and that the results proved that
these pills do work so that made me take the pills.’’ E FG
Perceived HIV-
prevention needs/risks
Risk of being exposed to HIV/desire to
protect HIV-negative status; discussion
of prevention in context of rape/forced
sex
‘‘As I said before, it made me want to protect myself. Before I
was involved in the study, I didn’t care as much as I do now.’’
T IDI
‘‘… I also knew that this pill will help me in any case like if I
was to be raped I would not be infected with HIV’’ D IDI
Use of concrete
adherence strategies
Strategies used for adherence ‘‘I didn’t set my phone or anything like that. I knew that if
Generations [a popular television series] is about to begin, I
would take my pill.’’ D FG
‘‘I would keep the tablets in my pocket so that I always
remember to drink the tablets’’ E IDI
Social support for use Support from partner/friend/family for
taking PrEP
‘‘My friends would also help me because they knew at a certain
time I was supposed to take the pill. So it was those kinds of
things that helped me.’’ T FG
‘‘The boyfriend that I was staying with was very supportive
and he always encourages me to drink the tablets.’’ E IDI
Barriers to PrEP use
Attributes of PrEP pills
(taste, smell)
Negative perceptions of pill attributes ‘‘Yes, at the beginning I was asking myself, how am I going to
be able to swallow this big pill and as time goes on, I was
able to swallow them.’’ D IDI
‘‘What I found difficult was the way it smelled, it made me
nauseous. So when the time came for me to take it, I had to
think hard about it. I wasn’t too happy taking it.’’ D FG
Side-effects attributed to
PrEP
Negative physical experiences attributed
to using PrEP in self or others
‘‘At first it was hard because they were not good for my
immune system but they have told me here that at first I
might have some side effects such as always feel[ing]
hungry, dizziness and they made me to have a small rush but
as time goes on, I got used to it.’’ D IDI
ARV-related stigma Fears that PrEP use will be misattributed
to HIV-treatment; participant will be
assumed to be HIV-positive
‘‘Plus negative response from friends … they compare
Truvada to ARVs because they know someone who was
taking the same medication and ended up being HIV
positive.’’ D IDI
‘‘We are very shy of walking around with pills in our bags,
because we are scared of what people would say, because let
us say you take out your pills and take them at the party,
some people won’t even ask- they will just say it’s an ARV.’’
E FG
Needs for privacy/non-
disclosure
Non-disclosure of study participation to
significant others, due to anticipated
stigma, misunderstanding or lack of
support
‘‘The problem was that I didn’t tell my boyfriend that I was
taking the Truvada. So when I went to his place, I wouldn’t
take it along’’ T FG
‘‘So you are now sitting with friends and you see that the time
is about to arrive. So what will they say if I were to take these
pills in front of them? My friends are going to judge me. So I
end up not taking them then.’’ E FG
AIDS Behav (2017) 21:1361–1375 1365
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PrEP: (1) A prioritization of contributions to the commu-
nity, which is consistent with a South African worldview
Ubuntu, and (2) a pervasive skepticism from both partici-
pants and communities about the trial, the product, and
procedures. The final theme also spanned across discourse
but was more reflective of ways in which women used and
did not use PrEP: (3) variability in approaches to regimen
uptake, persistence and adherence, between participants
and over time. Each cross-cutting theme is discussed in
detail below, and our integration of these themes into a
more comprehensive framework for understanding the
experiences of women in the study with hypotheses con-
cerning how factors at the participant, study and commu-
nity level interacted is provided through a proposed
Mutuality Framework.
Ubuntu Discourse about the personal protective value of
PrEP was present but the desire to contribute to something
good to the community was resounding. Note that this
differed from altruism in that participants reflected on
wanting efforts to be valued in their community specifi-
cally, highlighting strong reciprocity desires. Prioritization
of community well-being and feeling aligned with the
‘‘good’’ of one’s society is highly consistent with the
concept of Ubuntu. Ubuntu as a worldview emerged in the
mid-19th century to describe South African communities
working together as communities, and identifies that ‘hu-
manity’ exists in the interactions of groups of individuals.
It reflects beliefs that society, over individuals, gives
meaning and relevance, emphasizes collective responsi-
bility, and commitment towards health and well-being of
one’s community.
Skepticism Narratives reflected multiple experiences that
spoke to an underlying skepticism towards study-provided
PrEP and research more generally. This could be consid-
ered ‘‘healthy’’ skepticism in the sense that the cultural,
social and political history in communities participating in
this study have very recent and on-going experiences with
oppression and discrimination that promote skepticism as
an important safety precaution. Ongoing economic dis-
parities and poverty characterize daily life for most par-
ticipants. Medical establishments and biomedical research
centers, even those experienced as providing valuable
contributions to the participants, can be affiliated with
majority group(s) who are seen as responsible for past
injustices and ongoing disparities, or overt negligence
towards the safety and rights of members of the commu-
nity. It is important to note that skepticism as used here is
not an outright rejection of the study, but rather an
approach to the study that seeks ‘‘proof’’ to build trust or to
confirm that the study and products should not be trusted.
Importantly, high quality interactions with the study site
and staff are not sufficient to overcome negative expecta-
tions that are deeply seeded in the history of medical
services.
Variable Approaches to Study-Provided PrEP How par-
ticipants approached study-provided PrEP varied consid-
erably, from active avoidance of taking doses and
disclosure of such to the study team, to strong commit-
ments to use PrEP and advocacy in support of the study and
PrEP in the community and with other participants (PrEP
champions). Several women discussed avoiding PrEP use
entirely, and there was ample discourse about ‘‘other’’
Table 2 continued
Theme Defined as discourse on… Example quotes
Non-daily regimens
Sex-dependent doses Difficulty in determining whether or not
sex would occur (for pre-sex dosing)
and a mismatch between PrEP dosing
and the post-sex milieu
‘‘What would get me to forget is that—I live with my
boyfriend, right, okay. So maybe we’re lying on the bed
together and then sex just happens… Now my pills sit in a
divider and sometimes they are looking at me, but I am busy
at the moment… So I will have sex and then will wait for the
appropriate time for me to take the after sex pills.’’ E FG
‘‘The regimen that we were in was very difficult. Let’s say that
you are in town and your partner phones you and says:
‘‘Baby, please come this way when you’re finished in town.’’
Now you might not have a chance to stop off at home
because it could be late.’’ E FG
‘‘And sometimes, after sex, you want to sleep. Maybe you’re
tired. You don’t think about taking pills. Maybe you guys are
sitting together and talking since you don’t see each other so
often. So then you will forget the pills.’’ E IDI
‘‘After sex…. After I have just finished having sex, it’s nice to
sit back and relax a bit.’’ T FG
D daily regimen, T time-driven regimen, E event-driven regimen, IDI in depth interview participant, FG focus group participant
1366 AIDS Behav (2017) 21:1361–1375
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Table 3 Facilitators of and challenges to study participation
Theme Defined as discourse on… Example quotes
Facilitators of study participation
Personal experiences with HIV Desires to contribute towards HIV
prevention because of negative
impact of HIV on family, friends, or
community
‘‘I joined because I have a family member who passed on
because of HIV, so I decided to take part because I will
also benefit’’. E FG
Valuing the package of care
received as a participant
The unique benefits of being in the
study in terms of the medical care
and screening not easily available
outside of the study
‘‘You know, when we’re in the township, it can be difficult
for us to go test at the clinic and you won’t know what your
status is. So at least when you come here, you can find out
whether you are sick or not. So that supported me because I
got to know about my health.’’ E IDI
‘‘Maybe you just want to be cautious about your health
because here at the study they look at a lot of things you
don’t drink the pills only. That is what I liked’’ D IDI
Financial/economic compensation Reimbursements as motivating
participation in the study
‘‘They [other participants] also told me about the difficulties
they had but then they endured them. Another one told that
she is enduring them because you get money in this study,
like a lot of money.’’ T IDI
Positive feelings towards the research team Experiences, beliefs or feelings
towards study team that were
positive or motivating
‘‘It’s the way they treat us here at [site name]. It’s the way
the counselors also speak to us. They help you understand
the way in which these pills are meant to be taken. They
don’t force you.’’ T IDI
‘‘All the staff members were supportive I enjoy coming
here.’’ E IDI
Commitment to HIV prevention research Discourse of a shared vision with the
study in terms of working together
to make real contributions to HIV
prevention in their community
‘‘What made it easy for me was that it’s helping the
community. It’s not only helping me. So I am happy that
there were people who were supporting me.’’ D FG
‘‘I was following the instructions and I told myself that I was
doing it for a purpose. …to check as to whether this
research works for other people.’’ D IDI
Challenges to participation
Concerns about safety Study provided PrEP as unsafe or less
safe than informed by the research
team
‘‘People were not drinking the tablets because they were
flushing them down toilets because they were […]
experiencing side effects like headaches, stomach ache and
gaining weight.’’ E IDI
‘‘…I was scared of getting side effects hence I would throw
the pills away….’’ T IDI
‘‘I was okay but got worried because people were talking
about side effects.’’ T IDI
Community distrust of study and/or PrEP and
women’s participation in the study
Community rumors/convictions that
women would get HIV through
participation, have HIV, or
prioritize themselves and receiving
money for participation over the
community
‘‘Yoh! People say that they give you AIDS there!’’ E FG
‘‘…and my friend also said I am looking for trouble by
joining this study she had this whole idea of how I could
catch HIV.’’ T FG
‘‘And as for my friends… they were telling me that I am only
carrying on with this study because I wanted money’’ D
IDI
‘‘My family never encouraged me, especially my sister. She
just told me that I was going to get AIDS. She said: ‘They
take your blood and sell it.’’’ D FG
Negative clinic experiences Experiences at clinic site that were
negative or considered burdensome;
feelings of lack of transparency/
feeling accused
‘‘They irritated me because the same question is asked every
day: ‘‘address, contacts, phone numbers’’ – all the time…
He would ask the same questions.…Then when you come
back you have to explain again.’’ T FG
‘‘…and traditionally for us black people we don’t disclose
info like that easily to anyone, it’s embarrassing and
especially when they ask these unexpected questions.’’ T
FG
‘‘…it was all just irritating, and they would look you in the
face plus they wouldn’t say if you right or wrong, they
would just write down what you saying.’’ T FG
‘‘…the counselors were telling us that we are throwing the
pills away, which it was not all of us.’’ T IDI
D daily regimen, T time-driven regimen, E event-driven regimen, IDI in depth interview participant, FG focus group participant
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participants discarding drug, opening and closing the
electronic drug monitoring device (WisepillTM) to appear
adherent, and advising other participants to avoid PrEP
across study arms. However, there was also considerable
discussion about actively engaging other participants and
challenging negative stereotypes of participants and skep-
ticism in the community. In between the extremes of
intentional avoidance and ‘champions’, women discussed
variability in persistence (defined here as periods of con-
sistent engagement with the regimen or commitment to
trying to adhere) and execution of regimen (adherence
towards a regimen one is trying to take).
Synthesis of Findings: A Mutuality Framework
The cross-cutting and specific themes were used to develop
a framework to understand interactions between partici-
pant, community and study and how these influenced
women’s approaches to study-provided PrEP. Throughout
discourse a tension in negotiating dynamics between self,
study and community was clear. We characterize approa-
ches to study-provided PrEP as ranging from intentional
avoidance of PrEP dosing to strong persistence and
adherence. These approaches are situated within larger
social-cultural and resource contexts including; the value
of social and personal resources afforded through partici-
pation, the social-political community history with
biomedical research and medical institutions, identity
attributes (how participant and PrEP user is characterized
internally, to important others, in the community), cultural
world view emphasizing reciprocity to one’s community,
and product attributes and regimen burden or ease of use.
As indicated in Fig. 1, these ‘‘context’’ factors apply to the
formation, maintenance and/or movement between the
dynamics.
We adopt the term ‘dynamics’ to refer to the constel-
lation of factors influencing women’s experiences with
study-provided PrEP. These are not intended to charac-
terize people, rather they are ways of thinking about the
participant’s approach to study-provided PrEP at a given
point in time as the result of her negotiation of tensions and
synergies between herself, the study and her community.
Table 4 presents each dynamic in terms of characteriza-
tion, approach to study-provided PrEP, drivers of that
approach, and implications for intervention. The Mutuality
Framework (Fig. 1) and each dynamic detailed below
represent our integration of the narratives shared by women
in the study, while also expanding beyond the discourse to
incorporate findings in previous literature, multiple models
and theories pertinent to participatory research, socio-
ecological and social-determinants frameworks, and cul-
tural models. As such, the Mutuality Framework we pre-
sent is advised by factors identified in the current research
but extends beyond discourse to propose a new model
DYNAMICS are contextualized by: 
• Social and Personal Tangible and Intangible Resources 
• Social-Political History with research and site (skepticism) 
• Identity attributes (self, important others, research, community) as participant or product “user” 
• Product attributes Regimen Burden, Ease of use, Match to context
• Ubuntu (reciprocity to own community) 
Fig. 1 Mutuality framework
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Table 4 Dynamics in Mutuality Framework
Dynamic Approach to study and study-provided
PrEP
Caused by… Intervention implications and possible
strategies
Distrust Active, intentional avoidance of taking
product/PrEP.
‘‘…I was scared of getting side effects
hence I would throw the pills away….’’
T IDI
‘‘Others were just opening up the
container as [proof] that they were
taking them while they were not taking
them at all.’’ D IDI
Rejection of integrity of study (goals,
potential reciprocity to community) and
safety of products/PrEP and efficacy.
Strategies targeting changing beliefs in
safety, reciprocity, and efficacy of
product or integrity/relevance of
research findings (for efficacy trials)
Possible change strategies:
Community theatre with roles for ‘‘pro’’
and ‘‘cons’’ of drug safety or study
integrity where turns are taken in giving
voice to each ‘‘side’’, ending with
thoughts on what evidence/experiences
would convince one side or the other
Normalization of skepticism and overt
discussion of pros/cons allowing for
exploration of each
Community engagement and
mobilization events (i.e., CBPR
strategies)
Designs and programs that allow for
discontinuation or not using PrEP while
remaining in cohort
Creating ‘‘task force’’ teams of
participants who are tasked with and
resourced to perform fact-finding
missions about study and/or products
Uncertainty Variable persistence with study-provided
PrEP- on-again/off-again engagement
with trying to use study-provided PrEP.
‘‘Firstly, people say that we’re risking our
lives by getting involved in HIV
research.’’ E FG
‘‘But then I ended up thinking and
thinking and thinking about this,
whether there really isn’t anything
[HIV] they are giving us here.’’ D IDI
Skeptical exploration of whether or not to
trust study, PrEP, or providers of PrEP
(the research study, demonstration
project, or health agency)
In addition to changing beliefs (above),
strategies targeting enhancing beliefs of
safety, reciprocity, and efficacy
Possible change strategies:
PrEP study or program awareness
campaigns that invite open discussion
of potential medical mistrust from
social–historical and political
perspectives
Promote exploration of ambivalence as
reasonable and valid with a focus on
identifying what ‘‘data’’ would be
needed to assure participant
Adopt high transparency strategies that
explain aspects of procedures, protocol
or PrEP programs that are uncommon in
communities- for example, media
providing ‘‘proof’’ of legitimacy of
tests, samples or monitoring (video of
blood collection, where it is shipped
with pictures of labs, and disposal after
processing)
Engage peers, champions, and trusted
individuals to lead debates and
discussions about integrity, truth, and
reciprocity
If the PrEP agent is known to be
effective, emphasize this aspect of
potential value through multiple
modalities (pictures, media, theatre and
other methods of depicting efficacy)
Create opportunities to build sense of
ownership in trial- task participants
with conducting evaluations of
experiences at clinic, quality of care
received, and social harms (negative
experiences) in community that are fed
back to the research team and acted
upon
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offering a more complete, contextually-grounded, theoret-
ical conceptualization of experiences with biomedical
HIV-prevention.
Dynamic 1: Distrust
In the distrust dynamic one is anticipated to avoid use of
study-provided PrEP because of beliefs that the pills pro-
vided are unsafe and there is uncertainty about the
protection of participants in the study and limited expec-
tations of community or personal benefit from the per-
ceived high-risk of using study-provided PrEP. The aspect
of adherence most impacted in this dynamic is uptake.
Normative beliefs center on other participants also avoid-
ing use of the pills, and use of the pills reflecting naivete´ in
other participants. Women in this dynamic attempt to
protect other participants by encouraging non-use and
drawing from examples of experiencing side-effects and
Table 4 continued
Dynamic Approach to study and study-provided
PrEP
Caused by… Intervention implications and possible
strategies
Alignment Whereas persistence (trying to take
study-provided PrEP) is likely good;
execution adherence is anticipated to
vary on the basis of adherence skills
(strategies) and degree of positive
beliefs about value of PrEP and
adherence
‘‘… I wouldn’t do any of that [not take
the tablets] because I want to see if
these pills really, really work’’ T FG
‘‘I also wanted to continue taking it to the
end and if I hear that the pill did its job
and helped people, I will be proud of
that.’’ E FG
Provisional acceptance that the study and
products provided by study do benefit
self and community in ways that are
relevant and meaningful
Support should target maintaining trust in
study and positive beliefs about study-
provided PrEP use and optimizing
adherence.
Possible change strategies:
Barriers based discussions to identify
adherence challenges and resources and
skills that could be used to address them
Peer based support for adherence and
developing strategies to promote
adherence
Real-time monitoring may help to
provide reminders and problem solving
support as and when needed
Exploration of collected dosing data (as
available) to identify strengths, barriers
and potential strategies
Mutuality Both persistence and execution adherence
are generally high/good
‘‘… and I said: ‘‘Look here, ask me. And
don’t you dare say I have HIV, telling
everyone in this shop. We are doing
research here… to see whether the pills
can protect someone from HIV.’’ E FG
‘‘… [people] in the study must help them.
They must be proud to talk about the
pills and encourage other people.’’ T
FG
Ownership of PrEP and/or goals of the
study or program to the point of
advocacy
Support for uptake, persistence and
adherence are not generally needed in
this dynamic. Rather, avoiding eroding
mutuality is essential and developing
avenues for collaboration offers
opportunities to mobilize participant
groups and communities
Possible strategies to retain women in this
dynamic:
Create programs for peer mentors,
community champions, and other roles
that facilitate advocacy
Create sister-groups where women can
lead discussions among women in the
study or program
Create and use rotating participant
advisory panels where women can take
on valued leadership positions within
the study or program
Engage women in the development of a
plan for how results of the study or
program will be disseminated to
community and policy makers
Facilitate the creation of advocacy groups
that can lead local and regional efforts
to enhance awareness in communities
and represent community with local
health ministries, feeding back to
community progress and reasons for
delays in rolling out diverse prevention
strategies
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sero-conversions as proof of conviction that participants
are at risk. Efforts from the study team to debunk ‘mis-
information’ or rumors that minimize or fail to recognize
the legitimacy of concerns are expected to reinforce dis-
trust rather than reduce it. Women in this dynamic are
expected to avoid open discussions with the study team
about non-use of pills, or appearing non-adherent on self-
report or other measures that can be adjusted (e.g.,
announced pill-counts). Arguably, women experiencing
distrust are likely the most difficult to work with from a
study team perspective because their lack of trust in the
integrity and transparency of the study limit open dis-
course. They may, however, be identified through a lack of
drug concentration in combination with reports of high
adherence, which could open a window for discourse.
Studies that allow for participation without PrEP use (e.g.,
a no-PrEP arm) may be better positioned to decrease this
dynamic or offer opportunities to women to come off PrEP
while they consider or re-consider safety. We hypothesize
that the presence of this dynamic is likely in contexts where
there are driving structural or economic motivators to
participate- strong enough to persuade a woman who is
experiencing high levels of distrust and fear associated
with taking PrEP to nonetheless enroll and show up for
visits and procedures. In contexts where participation in the
study does not afford high-value, unique benefits, indi-
viduals experiencing distrust would not likely enroll or be
retained in the study. Interventions to promote movement
out of the distrust dynamic may include community based
participatory research practices to reduce some of the
factors driving the distrust dynamic, and any strategy that
dismantles beliefs about conspiracy, hidden risks, or dis-
regard for safety. Strategies that provide opportunities for
participants or patients to take on active roles in monitoring
quality of service delivery may similarly work to influence
beliefs in the integrity and transparency of programs.
Dynamic 2: Uncertainty
Individuals in this dynamic are expected to oscillate
between PrEP use and non-use in response to shifts
between feeling that PrEP use is safe and accurately rep-
resented by the study and feeling that PrEP use is unsafe
and that the study mischaracterizes risks involved. The
aspect of adherence most influenced in this dynamic is
hypothesized to be persistence- as periods of attempting to
follow the PrEP regimen is interspersed with periods of
avoiding it. Objective measures of drug concentrations may
mischaracterize individuals in this dynamic if the window
is too short (e.g., dosing in last 3 days or last week) and
per-week dosing may be a poor characterization as women
would be expected to have some weeks on PrEP and some
weeks off of it. Electronic dose monitoring devices may
have utility to the extent that they are not overtly manip-
ulated to appear persistent even when not taking PrEP.
Women’s experiences in this dynamic are characterized by
feeling pulled in different directions and the internal debate
over whether or not the pills and the study more generally
can be trusted is influenced by ongoing experiences with
the pills (e.g., side-effects), study team (e.g., positive and
negative experiences with study team members), other
participants (e.g., appeals from other participants to trust or
reject the study and, relatedly, PrEP), important others
(e.g., positive and negative influence of family members
and partners), and community (e.g., hearing rumors or
being ascribed negative traits [‘selling out’ community for
money] or positive ones from others in the community).
Normative beliefs of what other participants are doing with
their pills are fluid and not crystalized as definitely
dumping or definitely taking the pills, while hearing of
other women’s experiences is anticipated to be particularly
impactful in moving out of this dynamic. We conjecture
that the experience of this dynamic is tense and uncom-
fortable, which resolves only when beliefs shift towards
either distrust or stronger alignment with the study. It is
unclear how typical education and counseling on adherence
may play a part in this dynamic, as it could be argued that
clear information and support from the study team could
move the participant closer towards the aims of the study.
Alternatively, if information appears one-sided (reasons
why one should or must use PrEP) or dismissive (stating
PrEP is safe without further exploration), it could propel
rather than diminish concerns. Adherence counseling
focused on identification and remediation of barriers to
dosing assumes a shared interest in high adherence, which
is likely mismatched for those in the uncertainty dynamic
where the participant is still considering her willingness to
try a regimen. Like the distrust dynamic, Community
Based Participatory Research (CBPR) strategies, engaging
individuals in service delivery monitoring, and designs or
programs that allow for non-use of PrEP may be helpful.
Other strategies that promote discussions of uncertainty
and ambiguity focused on decision making around uptake
and persistence, preferably with the support of trusted
individuals (peers or participant ‘‘champions’’), may be
promising.
Dynamic 3: Alignment
Individuals in this dynamic are anticipated to be generally
engaged with trying to use PrEP, meaning they are likely
persistent but may have challenges to consistent dosing due
to commonly reported factors such as mustering motivation
to dose in specific situations, remembering, negotiating
privacy, or having doses accessible. Pill-use is character-
ized as persistent but with varying levels of adherence. The
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study, procedures and the pills are generally seen as safe
and the goals of the study are generally considered trust-
worthy, with potential to benefit one’s self and one’s
community. The balance of risk and reward is one of
minimal risk and possible benefit. Positive beliefs are
strong enough to build resilience to negative community
pressure, although actively shifting community beliefs is
not a priority. Normative beliefs about what other partici-
pants are doing, or not doing, exert less of an impact, and
one’s own experiences with PrEP, the study and significant
others are more influential. Women in this dynamic attempt
to follow recommendations and regimens, and have more
resilience in reporting non-adherence back to study team
members. A diverse set of strategies may be helpful for
women in this dynamic. Strategies using objective markers
of PrEP use may assist women in identifying patterns that
produce optimal and sub-optimal levels of protection. Of
note, the education and counseling offered in many studies
and programs that focus on unpacking potential facilitators
and barriers to adherence and building skills are likely to be
most appropriate for individuals in this dynamic, as open
discourse is possible and there is a shared goal of
adherence.
Dynamic 4: Mutuality
Individuals in this dynamic have a high degree of owner-
ship over PrEP and/or the goals of the study. Persistence
and adherence are both anticipated to be high and consis-
tent largely due to strong positive beliefs in PrEP and the
study’s ability to make lasting, real contributions to per-
sonal and community health and wellness. In this dynamic,
women are likely aware of participants in other dynamics
(particularly rejection and uncertainty) and community
concerns about the study or women participating in it. They
appreciate that normative beliefs for PrEP (and biomedical
prevention more generally) are diverse and fragmented in
the community. Unique to this dynamic is the response
women have to these experiences. They respond by overtly
challenging the beliefs of others, ‘vouching’ for the
integrity of the study and the product(s), and seeking out
opportunities in the community to shift beliefs. Their
advocacy positions them as ‘‘PrEP Champions’’ in both the
community outside of the study and within the study itself.
Their accumulated experiences with PrEP can position
them as more expert in terms of adherence than the study
team, who typically do not use PrEP or have lived expe-
rience with taking it. It is not clear that women in this
dynamic need study-provided support for persistence or
adherence, aside from being responsive to specific ques-
tions or issues raised by the participant. It may be more
important to avoid the introduction of experiences that may
move someone out of the mutuality dynamic, and create
new opportunities to allow for thus dynamic in the context
of research trials. Asking women in this dynamic to reflect
on doses missed (self-reported or objectively monitored)
may hold appeal to them if presented as for research or data
tracking purposes. However, if framed as for their own
benefit, women may feel such conversations with staff or
study team members, who themselves have little lived
experience with taking PrEP and advocating for it in their
communities, belittling or dismissive of their own exper-
tise. Support for adherence may be best positioned as ‘‘as
needed’’ for women in this dynamic. Other activities,
however, could help to keep women in this dynamic and
moreover could engage these women in assisting others.
Creating opportunities to serve as peer or participant
champions who could support other participants, speak at
community events, provide input into policy forums, or
advise the study team on recommendations for working
effectively with community and participants in other
dynamics would likely be more appropriate than a focus
exclusively on adherence.
Discussion
Discourse from predominantly young, unmarried women
who participated in the HPTN 067/ADAPT trial suggested
that approaches to open-label PrEP provided as daily,
twice-weekly plus post-sex dose, or pre- and post-sex
dosing varied, although many women spoke of high com-
mitment, persistence and adherence to their regimen.
Facilitators and barriers identified to dosing were generally
consistent with the literature on adherence to antiretroviral
therapy (ART) [30], prevention medications (e.g., hor-
monal contraception [31]), post-sex dosing challenges [32],
as well as recent evaluations of study-product use in FEM-
PrEP and VOICE [12–15]. In our sample of women,
specific challenges to non-daily dosing appeared centered
on the context in which participants had sex (e.g.,
unplanned, as available and typically outside of one’s
home) and the context surrounding post-sex (e.g., where
relaxation takes precedence over action-oriented preven-
tion behaviors such as dosing). Moreover, throughout the
discourse, women reflected on negotiating the potential use
of study-provided PrEP in a context where there were
substantial concerns about safety and integrity of the trial
and procedures, in many cases not knowing whether or not
the PrEP provided could be trusted or the study would
indeed benefit one’s community.
From the narratives collected, we constructed a Mutu-
ality Framework which proposes a characterization of how
the intersections, or dynamics, between self, community
and study impacted overall approaches to study-provided
PrEP. We propose diverse sets of strategies that could be
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implemented by study teams and/or PrEP implementation
programs as ways to enhance movement towards align-
ment. Typical adherence support offered within trials and
implementation programs that seek to optimize execution
adherence (doses taken as recommended) is well-matched
to the alignment dynamic, but may be poorly matched in
the remaining three dynamics (distrust, uncertainty, or
mutuality). Future research should target the evaluation of
CBPR strategies [33] and Good Participatory Practices
[34], as well as other innovative approaches, in shifting
levels of trust in both biomedical agents and biomedical
research. Efforts to engage social behavioural research to
measure dynamics that will influence PrEP uptake, through
the development of new or adaptation of existing scales
(i.e., the Group Based Medical Mistrust Scale [35, 36]),
characterising movement through dynamics over time and
in response to events and experiences, and strategies to
effectively shift distributions in our framework are
important next steps.
Although our results are specific to the group of partici-
pants engaged in this study and may not characterize experi-
ences of participants not included in the interviews or focus
groups, we do believe that the overall framework we devel-
oped is generalizable.We cannot, however, presently speak to
whether or not the data collected would have differed con-
siderably if the only regimen examined inHPTN067/ADAPT
was a proven one. Having other ‘investigational regimens’,
even if the drug itself was open label, may have created
challenges to perceived safety and clearly could have chal-
lenged feelings of efficacy. Even in light of this, we do believe
the Mutuality Framework may apply to other projects and
PrEP roll-out in areas where there may be skepticism towards
biomedical prevention, PrEP specifically, or the agencies that
provide it. Moreover, our framework is highly compatible
with models of innovation adoption [37], as well as process
models for behaviour adoption [38] and participatory
engagement models (cf., [39]), suggesting some applicability
to PrEP use more generally. However, future research is
needed to evaluate the replication and applicability of the
dynamics to ‘‘real-world’’ PrEP use.
The critical role of ‘‘medical mistrust’’ in treatment
adherence and research participation is well-established,
has clear roots in patterns of discrimination and promotes
widespread health disparities [40–43]. Our results add to
this literature by offering a nuanced framework for
understanding the manner in these factors may play out in
biomedical prevention studies. We believe many of the
core drivers we identify and manner in which systems
interact are generalizable to outside of a research trial.
Implications to PrEP roll-out may include careful attention
to the distribution of the Mutuality Framework dynamics in
targeted communities, and how planned dissemination of
PrEP may foster or mitigate skepticism, doubt, and distrust.
For example, when PrEP demonstration projects or PrEP-
specific clinics offer care beyond that which is available in
the community, larger distributions in the distrust and
uncertainty dynamics would be expected. Education and
awareness activities with trusted sources (peers, commu-
nity members, traditional healers) in trusted venues (faith-
based venues, community organizations) would be expec-
ted to speak to those experiencing distrust and uncertainty,
while scientific experts at town-halls, speaking events and
policy forums may speak more to those in alignment and
mutuality dynamics. Promoting and capacitating those in
mutuality to lead community campaigns and engage pol-
icy-makers directly may have high impact.
In summary, in combination with results from the main
HPTN 067/ADAPT study [16] in Cape Town, women in
sub-Saharan Africa found PrEP feasible and promising as a
self-directed tool for HIV-prevention. Women approached
PrEP in different ways, which we believe was dependent
on levels of perceived safety, trust in PrEP and those
providing it, and investments in protecting one’s commu-
nity either from PrEP or with it. Past literature has clearly
documented the need for effective, generalizable inter-
ventions to promote high levels of collaboration and trust
in communities for biomedical intervention, prevention,
and treatment [42, 44]. As PrEP implementation programs
unfold around the world, there is a real urgency to identify
how to ‘‘get it right’’. As suggested by our results, there are
many avenues to consider for how to potentially engage
communities around PrEP. Importantly, should our Mutu-
ality Framework offer a replicable, generalizable depiction
of experiences with PrEP, there are also avenues that could
distance communities and create substantial long-lasting
barriers in the adoption of biomedical HIV-prevention
innovations. Appreciating the cultural, political and his-
torical factors contextualizing PrEP and other biomedical
prevention strategies will be a critical ingredient in suc-
cessful implementation programs.
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